For more information about GenTel BioSurfaces, Inc., contact Alex D.
Vodenlich at 608-217-5587; email: alex@gentelbio.com
MADISON, Wis. – April 2, 2004. The Biotechnology Industry Organization (BIO)
has selected GenTel BioSurfaces, Inc. to present at its second annual BIO
Mid-America VentureForum in St. Louis, MO, May 4-5. This conference, a
collaboration between ten Midwestern states and the Biotechnology Industry
Organization, provides a venue for up-and-coming biotechnology and medical
device companies to meet with venture capitalists. GenTel is one of 75
early stage companies to be chosen.
“GenTel is looking forward to communicating our vision and business strategy
to members of the biotech venture community”, Alex Vodenlich, President,
remarked. “We have one product on the market and another scheduled for
release this summer. GenTel’s product focus and strong product development
pipeline, position us well to quickly become a leading supplier of
high-quality biochips for biomedical research.”
Aside from workshops and panel discussions focused on current financial and
biotech industry trends, the BIO Mid-America VentureForum provides the
selected companies a opportunity to meet with venture capitalists and
discuss their business plans in more detail.
GenTel’s mission is to become the premier supplier of high quality biochips
and biochip systems for the life science research, drug discovery and
diagnostics markets. GenTel’s business strategy includes forming corporate
alliances and partnerships to commercialize products resulting from its
internal product development efforts. GenTel also intends to build upon its
successful relationships with its University partners.
GenTel BioSurfaces, Inc. was founded in 2000 and is located in Madison,
Wisconsin’s University Research Park. The Company’s technology is centered
on surface chemistries for life sciences and encompasses microfluidics,
detection techniques and applications development.